2025 Q4 -tulosraportti
17 päivää sitten
‧49 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 838 | - | - | ||
| 160 | - | - | ||
| 602 | - | - | ||
| 1 189 | - | - | ||
| 100 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 943 081 | 1 943 081 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 943 081 | 1 943 081 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·5 t sitten · MuokattuAll-time low today. I have gone long in this stock with relatively small capital. It is either a stock that will be quickly revalued when it happens, because the product is good and needs to be established in the market. If this doesn't happen, I think it will be difficult for the company to survive.
·22 min sitten · MuokattuMuch pessimism. Is there no one who believes in any news that can move the stock between now and up until a Medicare application?- ·7 t sittenA little positive general treatment development, cancer treatment in Tromsø, Norway. Imagine if the headline was as one read it. Which it isn't. It is the radiation that is the radioactive missiles they are talking about, and not radioactive material from war materiel (my thoughts did go a bit to Iranian uranium, I must admit 🙈). https://www.nrk.no/tromsogfinnmark/forskere-ved-uit-og-unn-skal-bruke-_radioaktive-missiler_-mot-alvorlig-kreft-1.17804026 Subsequently, doctors can send a more powerful type of radioactive substance to the same cells. – We use a carrier molecule that recognizes special characteristics of cancer cells. It transports the radiation directly to them and kills the cancer cells without damaging the surrounding tissue, explains Sundset. The treatment is particularly aimed at patients where other forms of treatment no longer work. According to Sundset, cancer cells can eventually become resistant to treatments such as chemotherapy, radiation, and immunotherapy.
- ·8 t sittenRisk index predicts pancreatic neuroendocrine tumor recurrence Translated from Israeli Text is behind a registration wall (you who are medical personnel). Still a somewhat interesting headline https://www.e-med.co.il/specialties/oncology/2026/03/12/601301 Source: JAMA Surgery Prof. Amit Akirov 12/03/2026 No comments Risk index based on four factors – male gender, tumor size, grade according to the World Health Organization classification, and lymphovascular
- ·8 t sittenDoes anyone know if Immunovia/ PancreaSure is involved in this great news from Piedmont? https://www.linkedin.com/posts/andrew-page-md-193622106_our-team-is-indebted-to-many-donors-and-supporters-activity-7435783495425126401-x-oc "Our team is indebted to many donors and supporters of the Surgical Oncology and HPB Program at Piedmont. Last week we were honored by a transformational gift to create the Sherron Berg Early Detection Pancreatic Cancer Program, and I am humbled to now be the Sherron Berg Medical Director. Our team will continue to work towards earlier detection and access to research - with the shared vision for more cures from pancreatic cancer."
- ·8 t sitten · MuokattuStock price is 3 times below Carlsquare's base case now 😆 See Point 3 below Ah, so the market has squeezed it maximally to the lower limit. Do we have a potential rubber band here, or sorrow coming? AI tells about this: 1. The Short Seller Risk: The "Spring" is Coiled At 16 öre, the risk/reward for short sellers is shifting dramatically. The Squeeze Potential: Shorting a stock at these levels is picking up pennies in front of a steamroller. Any one of the "3 warm partner" talks turning into a signed deal, or the final New York CLEP approval, could cause a 50–100% gap-up overnight. Borrowing Costs: In a small-cap like IMMNOV, the cost to maintain a short position (the "borrow") can become expensive, and liquidity is thin. If they need to cover quickly, there aren't enough sellers at 16 öre to satisfy that demand without driving the price up vertically. 2. Why is it trading below the Base Case? If Carlsquare says it's worth 48 öre, why is it at 16? The market is currently "pricing in" the worst-case scenarios: The Dilution Discount: The market is skeptical about the Q3 2026 cash runway. Even though Jeff Borcherding said they are managing costs (6.6 MSEK/month vs. the expected 8–10), investors fear another rights issue before the Medicare revenue hits in 2027. The "Reverse Split" Hangover: Even though the board withdrew the 1:100 reverse split proposal in January 2026, the mere mention of it often scares away retail investors, leaving the stock in the hands of algorithms and shorts. 3. The 48 öre Base Case Logic Carlsquare’s 48 öre valuation (revised down from 65 öre in Feb 2026) is based on a Discounted Cash Flow (DCF) model that assumes: Medicare Submission: Happens on time in mid-2026. Reimbursement Flow: The $897 rate begins to turn into "meaningful revenue" by early 2027. Partner Launch: One of those 3 "warm" partners signs, giving them an instant sales force. Note: Carlsquare also has a Bear Case that sits much closer to the current price (around 15–18 öre), which assumes a slower sales ramp and a need for further equity financing.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
17 päivää sitten
‧49 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·5 t sitten · MuokattuAll-time low today. I have gone long in this stock with relatively small capital. It is either a stock that will be quickly revalued when it happens, because the product is good and needs to be established in the market. If this doesn't happen, I think it will be difficult for the company to survive.·22 min sitten · MuokattuMuch pessimism. Is there no one who believes in any news that can move the stock between now and up until a Medicare application?
- ·7 t sittenA little positive general treatment development, cancer treatment in Tromsø, Norway. Imagine if the headline was as one read it. Which it isn't. It is the radiation that is the radioactive missiles they are talking about, and not radioactive material from war materiel (my thoughts did go a bit to Iranian uranium, I must admit 🙈). https://www.nrk.no/tromsogfinnmark/forskere-ved-uit-og-unn-skal-bruke-_radioaktive-missiler_-mot-alvorlig-kreft-1.17804026 Subsequently, doctors can send a more powerful type of radioactive substance to the same cells. – We use a carrier molecule that recognizes special characteristics of cancer cells. It transports the radiation directly to them and kills the cancer cells without damaging the surrounding tissue, explains Sundset. The treatment is particularly aimed at patients where other forms of treatment no longer work. According to Sundset, cancer cells can eventually become resistant to treatments such as chemotherapy, radiation, and immunotherapy.
- ·8 t sittenRisk index predicts pancreatic neuroendocrine tumor recurrence Translated from Israeli Text is behind a registration wall (you who are medical personnel). Still a somewhat interesting headline https://www.e-med.co.il/specialties/oncology/2026/03/12/601301 Source: JAMA Surgery Prof. Amit Akirov 12/03/2026 No comments Risk index based on four factors – male gender, tumor size, grade according to the World Health Organization classification, and lymphovascular
- ·8 t sittenDoes anyone know if Immunovia/ PancreaSure is involved in this great news from Piedmont? https://www.linkedin.com/posts/andrew-page-md-193622106_our-team-is-indebted-to-many-donors-and-supporters-activity-7435783495425126401-x-oc "Our team is indebted to many donors and supporters of the Surgical Oncology and HPB Program at Piedmont. Last week we were honored by a transformational gift to create the Sherron Berg Early Detection Pancreatic Cancer Program, and I am humbled to now be the Sherron Berg Medical Director. Our team will continue to work towards earlier detection and access to research - with the shared vision for more cures from pancreatic cancer."
- ·8 t sitten · MuokattuStock price is 3 times below Carlsquare's base case now 😆 See Point 3 below Ah, so the market has squeezed it maximally to the lower limit. Do we have a potential rubber band here, or sorrow coming? AI tells about this: 1. The Short Seller Risk: The "Spring" is Coiled At 16 öre, the risk/reward for short sellers is shifting dramatically. The Squeeze Potential: Shorting a stock at these levels is picking up pennies in front of a steamroller. Any one of the "3 warm partner" talks turning into a signed deal, or the final New York CLEP approval, could cause a 50–100% gap-up overnight. Borrowing Costs: In a small-cap like IMMNOV, the cost to maintain a short position (the "borrow") can become expensive, and liquidity is thin. If they need to cover quickly, there aren't enough sellers at 16 öre to satisfy that demand without driving the price up vertically. 2. Why is it trading below the Base Case? If Carlsquare says it's worth 48 öre, why is it at 16? The market is currently "pricing in" the worst-case scenarios: The Dilution Discount: The market is skeptical about the Q3 2026 cash runway. Even though Jeff Borcherding said they are managing costs (6.6 MSEK/month vs. the expected 8–10), investors fear another rights issue before the Medicare revenue hits in 2027. The "Reverse Split" Hangover: Even though the board withdrew the 1:100 reverse split proposal in January 2026, the mere mention of it often scares away retail investors, leaving the stock in the hands of algorithms and shorts. 3. The 48 öre Base Case Logic Carlsquare’s 48 öre valuation (revised down from 65 öre in Feb 2026) is based on a Discounted Cash Flow (DCF) model that assumes: Medicare Submission: Happens on time in mid-2026. Reimbursement Flow: The $897 rate begins to turn into "meaningful revenue" by early 2027. Partner Launch: One of those 3 "warm" partners signs, giving them an instant sales force. Note: Carlsquare also has a Bear Case that sits much closer to the current price (around 15–18 öre), which assumes a slower sales ramp and a need for further equity financing.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 838 | - | - | ||
| 160 | - | - | ||
| 602 | - | - | ||
| 1 189 | - | - | ||
| 100 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 943 081 | 1 943 081 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 943 081 | 1 943 081 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 |
2025 Q4 -tulosraportti
17 päivää sitten
‧49 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·5 t sitten · MuokattuAll-time low today. I have gone long in this stock with relatively small capital. It is either a stock that will be quickly revalued when it happens, because the product is good and needs to be established in the market. If this doesn't happen, I think it will be difficult for the company to survive.·22 min sitten · MuokattuMuch pessimism. Is there no one who believes in any news that can move the stock between now and up until a Medicare application?
- ·7 t sittenA little positive general treatment development, cancer treatment in Tromsø, Norway. Imagine if the headline was as one read it. Which it isn't. It is the radiation that is the radioactive missiles they are talking about, and not radioactive material from war materiel (my thoughts did go a bit to Iranian uranium, I must admit 🙈). https://www.nrk.no/tromsogfinnmark/forskere-ved-uit-og-unn-skal-bruke-_radioaktive-missiler_-mot-alvorlig-kreft-1.17804026 Subsequently, doctors can send a more powerful type of radioactive substance to the same cells. – We use a carrier molecule that recognizes special characteristics of cancer cells. It transports the radiation directly to them and kills the cancer cells without damaging the surrounding tissue, explains Sundset. The treatment is particularly aimed at patients where other forms of treatment no longer work. According to Sundset, cancer cells can eventually become resistant to treatments such as chemotherapy, radiation, and immunotherapy.
- ·8 t sittenRisk index predicts pancreatic neuroendocrine tumor recurrence Translated from Israeli Text is behind a registration wall (you who are medical personnel). Still a somewhat interesting headline https://www.e-med.co.il/specialties/oncology/2026/03/12/601301 Source: JAMA Surgery Prof. Amit Akirov 12/03/2026 No comments Risk index based on four factors – male gender, tumor size, grade according to the World Health Organization classification, and lymphovascular
- ·8 t sittenDoes anyone know if Immunovia/ PancreaSure is involved in this great news from Piedmont? https://www.linkedin.com/posts/andrew-page-md-193622106_our-team-is-indebted-to-many-donors-and-supporters-activity-7435783495425126401-x-oc "Our team is indebted to many donors and supporters of the Surgical Oncology and HPB Program at Piedmont. Last week we were honored by a transformational gift to create the Sherron Berg Early Detection Pancreatic Cancer Program, and I am humbled to now be the Sherron Berg Medical Director. Our team will continue to work towards earlier detection and access to research - with the shared vision for more cures from pancreatic cancer."
- ·8 t sitten · MuokattuStock price is 3 times below Carlsquare's base case now 😆 See Point 3 below Ah, so the market has squeezed it maximally to the lower limit. Do we have a potential rubber band here, or sorrow coming? AI tells about this: 1. The Short Seller Risk: The "Spring" is Coiled At 16 öre, the risk/reward for short sellers is shifting dramatically. The Squeeze Potential: Shorting a stock at these levels is picking up pennies in front of a steamroller. Any one of the "3 warm partner" talks turning into a signed deal, or the final New York CLEP approval, could cause a 50–100% gap-up overnight. Borrowing Costs: In a small-cap like IMMNOV, the cost to maintain a short position (the "borrow") can become expensive, and liquidity is thin. If they need to cover quickly, there aren't enough sellers at 16 öre to satisfy that demand without driving the price up vertically. 2. Why is it trading below the Base Case? If Carlsquare says it's worth 48 öre, why is it at 16? The market is currently "pricing in" the worst-case scenarios: The Dilution Discount: The market is skeptical about the Q3 2026 cash runway. Even though Jeff Borcherding said they are managing costs (6.6 MSEK/month vs. the expected 8–10), investors fear another rights issue before the Medicare revenue hits in 2027. The "Reverse Split" Hangover: Even though the board withdrew the 1:100 reverse split proposal in January 2026, the mere mention of it often scares away retail investors, leaving the stock in the hands of algorithms and shorts. 3. The 48 öre Base Case Logic Carlsquare’s 48 öre valuation (revised down from 65 öre in Feb 2026) is based on a Discounted Cash Flow (DCF) model that assumes: Medicare Submission: Happens on time in mid-2026. Reimbursement Flow: The $897 rate begins to turn into "meaningful revenue" by early 2027. Partner Launch: One of those 3 "warm" partners signs, giving them an instant sales force. Note: Carlsquare also has a Bear Case that sits much closer to the current price (around 15–18 öre), which assumes a slower sales ramp and a need for further equity financing.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 838 | - | - | ||
| 160 | - | - | ||
| 602 | - | - | ||
| 1 189 | - | - | ||
| 100 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 943 081 | 1 943 081 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 943 081 | 1 943 081 | 0 | 0 |